Oncology

Christine Coughlin, MD, PhD, on TRACK-NK Technology in Non-Small Cell Lung Cancer

The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.

Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy

The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.

Allogeneic Anti-CD7 CAR-T Demonstrates Promising Results in Hematological Malignancies

Among the 11 patients evaluated for efficacy, 9 patients (81.8%) had objective responses at 28 days.